CPIX

Cumberland Pharmaceuticals

CPIX

Attention (50-day avg)0%

Attention rank (50-day avg)#3,067

Bullish sentiment (50-day avg)98%

Price to earnings ratio-40.6

Market capitalization115.7M

Earnings per share-0.22

Dividend yield (TTM)—

Revenue (annual)44.5M

Net income (annual)-2.9M

Social

What share of all stock conversation is about CPIX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% 0	0% 0

Aug 3

The company may provide an update on the extended study results for DMD, possibly through a scientific conference or publication, as early as tomorrow.
The author remains bullish on the DMD indication and is encouraged by the Phase 2A Cancer Metastasis trial data, suggesting that the drug may be meaningfully partnered or sold.
The company is expected to provide a company update with second-quarter financial results after the market closes on August 4, 2026.

Generated by AI

Sentiment

Of the messages about CPIX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100%	92.31% -5.65	87.35% +4.26
Bearish	0%	0%	7.69% +5.65	12.65% -4.26

Bullish· Apr 24

The stock has a high short interest of 329% and a small float of 8M, making it a potential candidate for a squeeze.
The company has a strong pipeline with multiple programs in development, including ifetroban, which has shown promise in Phase 2 trials for Duchenne muscular dystrophy.
The stock has a strong fundamental case, with four consecutive quarters of earnings beats, a $100M cash infusion pending, and a deal with Apotex to sell its branded drug portfolio.

Bearish· Apr 24

The company's directors and executives hold about 41% of outstanding shares, which could provide support for the stock, but the selling pressure today is likely due to traders, shorts, and profit-taking rather than insider selling.
The stock's float is tiny, ranging from 5M to 8M shares, making it vulnerable to short squeezes if it breaks above $3.90.
The stock's recent price action is likely a result of market makers manipulating the price to create fear and trigger stops, rather than genuine weakness, which could reset the stock before the next move higher.

Generated by AI

Topics

Of the messages about CPIX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	0%	0%	66.67%	57.46%
Technical Analysis	100%	100%	33.33%	38.51%
Earnings	0%	0%	0%	1.61%
Analysts	0%	0%	0%	0%
Controversies	0%	0%	0%	0%
Macro	0%	0%	0%	2.42%

Announcements· Apr 23

Cumberland Pharmaceuticals Inc. ($CPIX) announces a strategic transaction with Apotex to integrate its commercial business, unlocking $100 million in value and sharpening its orphan-drug focus.
The transaction involves Apotex acquiring Cumberland's line of branded pharmaceuticals for $100 million in cash, subject to shareholder approval.
Cumberland Pharmaceuticals will retain its pipeline, including three Phase II programs using ifetroban, a thromboxane inhibitor, and is poised to pivot to its orphan-drug pipeline.

Technical Analysis· Apr 23

$CPIX broke through $3.65 resistance with 42.28M volume, reaching a +51.15% gain and confirming a target of $7.13.
The stock's momentum is explosive, driven by Opaganib's AACR data on neuroblastoma and triple-negative breast cancer.
The RSI is no longer lying on the bottom, indicating a potential continuation of the stock's upward momentum.

Generated by AI

Community

Of the messages about CPIX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	77.27%	58.95%
Newcomers	0%	0%	22.73%	41.05%

Regulars· Apr 23

$CPIX is experiencing a strong uptrend, with a 92% increase, and needs to break the high of the day at 5.89 to continue its momentum.
The company's stock price is up 62% and climbing, but it requires more volume to maintain its trend and break the new high of the day at 5.18.
Cumberland Pharmaceuticals Inc. has announced a strategic transaction, and its stock price has surged 20% since, with the potential for a flat top breakout and continued growth.

Newcomers· Apr 23

Newcomers are attracted to $CPIX due to its high volume and volatility, but some find it reasonably priced despite the hype.
The stock is being watched for potential continuation through key levels, including a previous pre-market double top resistance at $6.04.
The recent FDA approval for an expanded indication on Caldolor, a non-opioid pain management product, is seen as a significant catalyst for the stock's 80% premarket price increase.

Generated by AI

News

Cumberland Pharmaceuticals: Pivot Into Drug Development Creates Risk, Opportunity (CPIX)

1mo agoSeeking Alpha

Cumberland Pharmaceuticals Inc (CPIX) (Q2 2026) Earnings Call Highlights: Strategic ...

Company closes $100M Apotex deal, declares special dividend, and advances key clinical programs including DMD, systemic sclerosis, and IPF.

1mo agoYahoo Finance

Earnings call transcript: Cumberland Pharmaceuticals swings on Q2 2026 reset

1mo agoInvesting.com

Cumberland Pharmaceuticals Q2 Earnings Call Highlights

Cumberland Pharmaceuticals (NASDAQ:CPIX) reported a second-quarter operating loss of $3.1 million as it prepared to transition from a commercial-stage specialty pharmaceutical company into an innovation-focused biopharmaceutical business following the sale of its branded U.S. commercial portfolio to

1mo agoYahoo Finance

CUMBERLAND PHARMACEUTICALS REPORTS COMPANY UPDATE & Q2 2026 FINANCIAL RESULTS

1mo agoYahoo Finance

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE COMPANY UPDATE & Q2 2026 FINANCIAL RESULTS

Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), an innovation-focused biopharmaceutical company committed to developing new products for rare diseases, announced today that it will provide a company update with second quarter 2026 financial results after the market closes on Tuesday, August 4, 2026.

2mo agoYahoo Finance

Also Discussed

Investors talking about CPIX also mention

#	Name	Attention
1	Pasithea Therapeutics Corp.KTTA	0%0
2	PTPI - Petros Pharmaceuticals, Inc.	——
3	LIPO - Lipella Pharmaceuticals Inc.	——
4	Longeveron Inc. Class A Common StockLGVN	0%0
5	Inspira Technologies Oxy B.H.N. Ltd.IINN	0%new
6	Invesco BulletShares 2031 Municipal Bond ETFBSMV	0%0
7	Local Bounti CorporationLOCL	0%0
8	Defiance Large Cap ex-Mag 7 ETFXMAG	0%new
9	Direxion Daily NFLX Bull 2X ETFNFXL	0%new
10	Lendway Inc.LDWY	0%new

Cumberland Pharmaceuticals Inc.

Healthcare
Drug Manufacturers - Specialty & Generic

Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing, acquiring, and commercializing branded prescription medicines for hospital acute care and other specialized treatment settings. Cumberland Pharmaceuticals markets a portfolio of approved products used in areas such as pain and fever management, nausea and vomiting prevention, constipation, hyponatremia, and certain bacterial infections. Its business centers on delivering therapies for physicians, hospitals, and patients who need targeted prescription treatments in areas where standard options may be limited or highly specialized. The company also operates in therapeutic markets including gastroenterology, oncology support, and critical care, reflecting its emphasis on products used in acute and hospital-based care. Cumberland Pharmaceuticals plays a niche role in the healthcare market by focusing on prescription medicines designed for specific clinical needs rather than broad consumer health products.

Website

Location

1600 West End Avenue

Nashville, TN, 37203

United States

Social

What share of all stock conversation is about CPIX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% 0	0% 0

Aug 3

The company may provide an update on the extended study results for DMD, possibly through a scientific conference or publication, as early as tomorrow.
The author remains bullish on the DMD indication and is encouraged by the Phase 2A Cancer Metastasis trial data, suggesting that the drug may be meaningfully partnered or sold.
The company is expected to provide a company update with second-quarter financial results after the market closes on August 4, 2026.

Generated by AI

Sentiment

Of the messages about CPIX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100%	92.31% -5.65	87.35% +4.26
Bearish	0%	0%	7.69% +5.65	12.65% -4.26

Bullish· Apr 24

The stock has a high short interest of 329% and a small float of 8M, making it a potential candidate for a squeeze.
The company has a strong pipeline with multiple programs in development, including ifetroban, which has shown promise in Phase 2 trials for Duchenne muscular dystrophy.
The stock has a strong fundamental case, with four consecutive quarters of earnings beats, a $100M cash infusion pending, and a deal with Apotex to sell its branded drug portfolio.

Bearish· Apr 24

The company's directors and executives hold about 41% of outstanding shares, which could provide support for the stock, but the selling pressure today is likely due to traders, shorts, and profit-taking rather than insider selling.
The stock's float is tiny, ranging from 5M to 8M shares, making it vulnerable to short squeezes if it breaks above $3.90.
The stock's recent price action is likely a result of market makers manipulating the price to create fear and trigger stops, rather than genuine weakness, which could reset the stock before the next move higher.

Generated by AI

Topics

Of the messages about CPIX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	0%	0%	66.67%	57.46%
Technical Analysis	100%	100%	33.33%	38.51%
Earnings	0%	0%	0%	1.61%
Analysts	0%	0%	0%	0%
Controversies	0%	0%	0%	0%
Macro	0%	0%	0%	2.42%

Announcements· Apr 23

Cumberland Pharmaceuticals Inc. ($CPIX) announces a strategic transaction with Apotex to integrate its commercial business, unlocking $100 million in value and sharpening its orphan-drug focus.
The transaction involves Apotex acquiring Cumberland's line of branded pharmaceuticals for $100 million in cash, subject to shareholder approval.
Cumberland Pharmaceuticals will retain its pipeline, including three Phase II programs using ifetroban, a thromboxane inhibitor, and is poised to pivot to its orphan-drug pipeline.

Technical Analysis· Apr 23

$CPIX broke through $3.65 resistance with 42.28M volume, reaching a +51.15% gain and confirming a target of $7.13.
The stock's momentum is explosive, driven by Opaganib's AACR data on neuroblastoma and triple-negative breast cancer.
The RSI is no longer lying on the bottom, indicating a potential continuation of the stock's upward momentum.

Generated by AI

Community

Of the messages about CPIX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	77.27%	58.95%
Newcomers	0%	0%	22.73%	41.05%

Regulars· Apr 23

$CPIX is experiencing a strong uptrend, with a 92% increase, and needs to break the high of the day at 5.89 to continue its momentum.
The company's stock price is up 62% and climbing, but it requires more volume to maintain its trend and break the new high of the day at 5.18.
Cumberland Pharmaceuticals Inc. has announced a strategic transaction, and its stock price has surged 20% since, with the potential for a flat top breakout and continued growth.

Newcomers· Apr 23

Newcomers are attracted to $CPIX due to its high volume and volatility, but some find it reasonably priced despite the hype.
The stock is being watched for potential continuation through key levels, including a previous pre-market double top resistance at $6.04.
The recent FDA approval for an expanded indication on Caldolor, a non-opioid pain management product, is seen as a significant catalyst for the stock's 80% premarket price increase.

Generated by AI

Cumberland Pharmaceuticals

Social

Aug 3

Bullish· Apr 24

Bearish· Apr 24

Announcements· Apr 23

Technical Analysis· Apr 23

Regulars· Apr 23

Newcomers· Apr 23

Cumberland Pharmaceuticals: Pivot Into Drug Development Creates Risk, Opportunity (CPIX)

Cumberland Pharmaceuticals Inc (CPIX) (Q2 2026) Earnings Call Highlights: Strategic ...

Earnings call transcript: Cumberland Pharmaceuticals swings on Q2 2026 reset

Cumberland Pharmaceuticals Q2 Earnings Call Highlights

CUMBERLAND PHARMACEUTICALS REPORTS COMPANY UPDATE & Q2 2026 FINANCIAL RESULTS

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE COMPANY UPDATE & Q2 2026 FINANCIAL RESULTS

Also Discussed

Cumberland Pharmaceuticals Inc.

Company Information

Location

Cumberland Pharmaceuticals: Pivot Into Drug Development Creates Risk, Opportunity (CPIX)

Cumberland Pharmaceuticals Inc (CPIX) (Q2 2026) Earnings Call Highlights: Strategic ...

Earnings call transcript: Cumberland Pharmaceuticals swings on Q2 2026 reset

Cumberland Pharmaceuticals Q2 Earnings Call Highlights

CUMBERLAND PHARMACEUTICALS REPORTS COMPANY UPDATE & Q2 2026 FINANCIAL RESULTS

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE COMPANY UPDATE & Q2 2026 FINANCIAL RESULTS

Also Discussed

Social

Aug 3

Bullish· Apr 24

Bearish· Apr 24

Announcements· Apr 23

Technical Analysis· Apr 23

Regulars· Apr 23

Newcomers· Apr 23